These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 33109412)

  • 1. Corrigendum to "Blocking exposed PD-L1 elicited by nanosecond pulsed electric field reverses dysfunction of CD8 + T cells in liver cancer" [Canc. Lett. 495 (2020) 1-11].
    Qian J; Chen T; Wu Q; Zhou L; Zhou W; Wu L; Wang S; Lu J; Wang W; Li D; Xie H; Su R; Guo D; Liu Z; He N; Yin S; Zheng S
    Cancer Lett; 2021 Feb; 498():242. PubMed ID: 33109412
    [No Abstract]   [Full Text] [Related]  

  • 2. Corrigendum to"PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responsesˮ [Canc. Lett. 476 (2020) 170-182].
    Tian H; Kang Y; Song X; Xu Y; Chen H; Gong X; Zhang W; Xu Y; Xia X; Gao X; Yao W
    Cancer Lett; 2021 Feb; 499():4. PubMed ID: 32747014
    [No Abstract]   [Full Text] [Related]  

  • 3. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.
    Shi F; Shi M; Zeng Z; Qi RZ; Liu ZW; Zhang JY; Yang YP; Tien P; Wang FS
    Int J Cancer; 2011 Feb; 128(4):887-96. PubMed ID: 20473887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
    Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
    Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum to "Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathway" [Canc. Lett. (2009) 282(2) 167-76 doi:10.1016/j.canlet.2009.03.003].
    Bhui K; Prasad S; George J; Shukla Y
    Cancer Lett; 2020 Jun; 480():48. PubMed ID: 32035655
    [No Abstract]   [Full Text] [Related]  

  • 6. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
    Waeckerle-Men Y; Starke A; Wüthrich RP
    Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum to "Exosome-encapsulated miRNAs contribute to CXCL12/CXCR4-induced liver metastasis of colorectal cancer by enhancing M2 polarization of macrophages" [Canc. Lett. 474 (2020) 36-52].
    Wang D; Wang X; Si M; Yang J; Sun S; Wu H; Cui S; Qu X; Yu X
    Cancer Lett; 2022 Jan; 525():200-202. PubMed ID: 34785089
    [No Abstract]   [Full Text] [Related]  

  • 8. Multi-Parametric Study of the Viability of
    Mi Y; Li P; Liu Q; Xu J; Yang Q; Tang J
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819876918. PubMed ID: 31551008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum to "Targeting autophagy in cancer stem cells as an anticancer therapy" [Canc. Lett. 393 (2017) 33-39].
    Lei Y; Zhang D; Yu J; Dong H; Zhang J; Yang S
    Cancer Lett; 2018 Mar; 416():149. PubMed ID: 29307478
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer" [Canc. Lett. 438 (2018, Dec 1) 165-173].
    Lin CC; Lo MC; Moody R; Jiang H; Harouaka R; Stevers N; Tinsley S; Gasparyan M; Wicha M; Sun D
    Cancer Lett; 2020 Jun; 480():51. PubMed ID: 32229161
    [No Abstract]   [Full Text] [Related]  

  • 12. A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model.
    Lin Z; Zhang Y; Cai H; Zhou F; Gao H; Deng L; Li R
    Mol Ther Oncolytics; 2019 Sep; 14():222-232. PubMed ID: 31384666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint.
    Xu S; Tao Z; Hai B; Liang H; Shi Y; Wang T; Song W; Chen Y; OuYang J; Chen J; Kong F; Dong Y; Jiang SW; Li W; Wang P; Yuan Z; Wan X; Wang C; Li W; Zhang X; Chen K
    Nat Commun; 2016 May; 7():11406. PubMed ID: 27147225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
    Hou Y; Nitta H; Wei L; Banks PM; Lustberg M; Wesolowski R; Ramaswamy B; Parwani AV; Li Z
    Breast J; 2018 Nov; 24(6):911-919. PubMed ID: 30230111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.
    Fisicaro P; Valdatta C; Massari M; Loggi E; Biasini E; Sacchelli L; Cavallo MC; Silini EM; Andreone P; Missale G; Ferrari C
    Gastroenterology; 2010 Feb; 138(2):682-93, 693.e1-4. PubMed ID: 19800335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum to "B4GALT3 up-regulation by miR-27a contributes to the oncogenic activity in human cervical cancer cells." [Canc. Lett. 375 (2016) 284-292].
    Sun Y; Yang X; Liu M; Tang H
    Cancer Lett; 2020 Nov; 493():16-18. PubMed ID: 32823018
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3" [Canc Lett 379 (2016) 124-133].
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2020 Nov; 493():13-15. PubMed ID: 32823017
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells" [Canc. Lett. 412 (2018) 297-307].
    Le HT; Nguyen HT; Min HY; Hyun SY; Kwon S; Lee Y; Le THV; Lee J; Park JH; Lee HY
    Cancer Lett; 2018 Jun; 424():136. PubMed ID: 29573834
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "FLLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway" [Canc. Lett. 363 (2015) 166-175].
    Haque A; Rahman MA; Fuchs JR; Chen Z; Khuri FR; Shin DM; Amin ARMR
    Cancer Lett; 2021 Feb; 498():249-250. PubMed ID: 33092912
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer" [Canc. Lett. 423 (2018) 36-46].
    Lu T; Li Z; Yang Y; Ji W; Yu Y; Niu X; Zeng Q; Xia W; Lu S
    Cancer Lett; 2018 Sep; 431():244. PubMed ID: 29754994
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.